Development and Validation of a Predictive Model of Pain Modulation Profile to Guide Chronic Pain Treatment: A Study Protocol by Vincenot, Matthieu et al.
METHODS
published: 15 February 2021
doi: 10.3389/fpain.2021.606422
Frontiers in Pain Research | www.frontiersin.org 1 February 2021 | Volume 2 | Article 606422
Edited by:
Vivianne L. Tawfik,
Stanford University, United States
Reviewed by:
Marc Landry,
Université de Bordeaux, France
Kristin Schreiber,






†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Pain Mechanisms,
a section of the journal
Frontiers in Pain Research
Received: 14 September 2020
Accepted: 13 January 2021
Published: 15 February 2021
Citation:
Vincenot M, Coulombe-Lévêque A,
Sean M, Camirand Lemyre F,
Gendron L, Marchand S and
Léonard G (2021) Development and
Validation of a Predictive Model of
Pain Modulation Profile to Guide
Chronic Pain Treatment: A Study
Protocol. Front. Pain Res. 2:606422.
doi: 10.3389/fpain.2021.606422
Development and Validation of a
Predictive Model of Pain Modulation
Profile to Guide Chronic Pain
Treatment: A Study Protocol
Matthieu Vincenot 1,2, Alexia Coulombe-Lévêque 1,2, Monica Sean 1,3,
Félix Camirand Lemyre 4,5, Louis Gendron 3,4, Serge Marchand 2† and
Guillaume Léonard 1,6*†
1 Research Center on Aging, Université de Sherbrooke, Sherbrooke, QC, Canada, 2 Faculty of Medicine and Health Sciences,
Université de Sherbrooke, Sherbrooke, QC, Canada, 3Department of Pharmacology-Physiology, Faculty of Medicine and
Health Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Centre de Recherche du Centre Hospitaliser
Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 5Département de Mathématiques, Faculté des Sciences, Université
de Sherbrooke, Sherbrooke, QC, Canada, 6 Faculty of Medicine and Health Sciences, School of Rehabilitation, Université de
Sherbrooke, Sherbrooke, QC, Canada
Introduction: Quantitative sensory testing is frequently used in research to assess
endogenous pain modulation mechanisms, such as Temporal Summation (TS) and
Conditioned Pain Modulation (CPM), reflecting excitatory and inhibitory mechanisms,
respectively. Numerous studies found that a dysregulation of these mechanisms is
associated with chronic pain conditions. In turn, such a patient’s “profile” (increased
TS and/or weakened CPM) could be used to recommend different pharmacological
treatments. However, the procedure to evaluate these mechanisms is time-consuming
and requires expensive equipment that is not available in the clinical setting. In this study,
we aim to identify psychological, physiological and socio-demographic markers that
could serve as proxies to allow healthcare professionals to identify these pain phenotypes
in clinic, and consequently optimize pharmacological treatments.
Method: We aim to recruit a healthy participant cohort (n = 360) and a chronic pain
patient cohort (n= 108). Independent variables will include psychological questionnaires,
pain measurements, physiological measures and sociodemographic characteristics.
Dependent variables will include TS and CPM, which will be measured using quantitative
sensory testing in a single session. We will evaluate one prediction model and two
validation models (for healthy and chronic pain participants) using multiple regression
analysis between TS/CPM and our independent variables. The significance thresholds
will be set at p = 0.05, respectively.
Perspectives: This study will allow us to develop a predictive model to compute the pain
modulation profile of individual patients based on their biopsychosocial characteristics.
The development of the predictive model is the first step toward the overarching goal
of providing clinicians with a set of quick and cheap tests, easily applicable in clinical
practice to orient pharmacological treatments.
Keywords: chronic pain, temporal summation, conditional pain modulation, pain modulation profile,
catecholamines, clinical feasibility
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INTRODUCTION
Chronic pain, which affects one in five people worldwide (1),
has been defined as pain that persists beyond the usual healing
time (2). However, merely relying on this temporal aspect
is not enough to account for the complexity of chronic
pain vs. acute pain. As such, the notion of inadequate
response to treatment and significant, lasting alterations
of functional and psychosocial status have increasingly
been recognized as an integral part of this condition (3).
Several factors have been associated with chronic pain,
including physical limitations (4, 5), cognitive impairments
(6), and psychological conditions, such as anxiety and
depression (7).
Dysregulations of endogenous pain modulating systems are
also thought to be involved in the development of chronic pain.
These dysregulations include increases in pain facilitation [which
amplify our body’s alertness (8)], and decreases in pain inhibition
[which triggers diffuse hypoalgesia (9)]. These endogenous pain
modulation mechanisms can be measured using quantitative
sensory testing based on Temporal Summation (TS) and
Conditioned Pain Modulation (CPM), respectively. Both of these
testing paradigms have high test-retest reliability (10–12).
TS is the psychophysical correlate of central sensitization,
which is defined as an increased responsiveness of second
order neurons (located in the spinal cord) to afferent C-
fibers (13) resulting in a heightened pain perception (14).
Increased TS is thought to be involved in various chronic
pain conditions, such as fibromyalgia (14, 15), chronic low
back pain (16), and painful knee osteoarthritis (17). CPM, on
the other hand, refers to the phenomenon wherein a noxious
stimulation results in widespread hypoalgesia (18), akin to the
diffuse noxious inhibitory control involving a spino-bulbo-spinal
loop studied in animal models (9, 19). Weakened CPM is found
in chronic pain conditions, such as chronic tension headaches
(20), provoked vestibulodynia (21), atypical trigeminal neuralgia
(22), temporomandibular disorders (23), fibromyalgia (24), and
irritable bowel syndrome (23).
TS and CPM measures can be used to identify individuals
at risk of developing chronic pain (25). For example, the
amplitude of pre-operative TS is correlated with the intensity of
post-operative pain (26), while a placebo-controlled study has
found that weaker CPM is associated with a better response
to duloxetine (a serotonin-noradrenalin reuptake inhibitor) in
patients suffering from neuropathic pain (27). This line of
research has led authors to suggest that it is the presence of
specific deficits in endogenous pain modulation mechanisms,
rather than the type of chronic pain, that best predicts response to
treatment (28, 29). Indeed, according to Yarnitsky and colleagues,
each individual can be placed along a spectrum ranging from an
antinociceptive (normal TS/effective CPM) to a pronociceptive
(increased TS/weak CPM) profile, and as such should be more
receptive to an individually tailored treatment that specifically
counteracts their deficits (25).
The evaluation of these endogenous mechanisms could
therefore prove useful in the clinic, by providing healthcare
professionals with valuable information regarding the pain
modulation profile of patients to help them choose the
most appropriate pharmacological approach. Unfortunately,
to the best of our knowledge, no study has attempted to
estimate the amplitude of TS and CPM using readily accessible
measures. Protocols currently used to evaluate endogenous
pain modulation mechanisms are time consuming and require
expensive, complex equipment that would not be practical for
daily clinical practice. As such, an alternative approach, which
would allow clinicians to easily estimate their patient’s CPM
and TS using readily available tests, would be highly relevant to
clinical practice.
Despite the lack of predictive models using TS and CPM
as outcome, numerous association studies suggest that certain
factors influence endogenous mechanisms. TS and CPM have
long been known to be affected by age and sex (30–
38), but more recently they have also been linked to a
number of other psychophysiological variables. For instance,
TS is consistently associated with pain catastrophizing (39–
42), whereas CPM is modulated by both catastrophizing (43,
44) and expectations (45); additionally, a wide array of other
psychological factors have been related to pain mechanisms,
albeit in a method-dependent manner [for a review, see
(46)]. Certain physiological factors, such as blood pressure,
also seem to correlate with TS/CPM (47, 48) response,
whereas others, such as activation of endocannabinoid and
opioid systems, are known to directly contribute to pain
inhibition (49–51). Moreover, a lower plasma concentration
of dopamine (52) and catecholamines (norepinephrine and
serotonin) (53) is associated with deficient CPM in chronic
pain patients and, interestingly, it seems that this low plasma
concentration is attributable to genetic polymorphisms, which
suggests that CPM deficiency could in fact have a genetic
correlate (54).
Different approaches have been developed (based on
similar theoretical frameworks) to assess endogenous
mechanisms. For TS, constant (47, 53–55) and pulsed
(15, 31, 56, 57) nociceptive stimulations are commonly
used, with a large variety of stimuli (58). For CPM,
TABLE 1 | Eligibility criteria.
Chronic pain patients Healthy Participants
Inclusion
criteria
Able to understand instructions
18–79 years of age
Chronic Pain condition (>6
months)





Pregnancy, or post-partum (<1 year) status
Active cancer or cancer-related pain
Cardiac or vascular diseases
History of psychotic or neurocognitive disorder
Regular use of recreational substances
Acute or chronic arm injury, including impaired sensitivity
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protocols include parallel (27, 34, 59, 60) or sequential
(35, 38, 61–63) paradigms. In this context, the heterogeneity
of the aforementioned studies and approaches makes it
difficult to draw any meaningful generalization (64). Moreover,
these factors have yet to be systematically evaluated within a
single study.
The first objective of this study is to develop and validate
a predictive model to estimate the amplitude of TS and CPM.
Our second objective is to estimate reference values of these
endogenous excitatory and inhibitory modulation mechanisms
of pain in a healthy population.
METHODS
Participants
Our participants will take part in a single experimental
session, taking place at the Centre de Recherche du CHUS
(Sherbrooke, Quebec, Canada). Eligibility criteria (56) are
listed in Table 1. We will ask that participants refrain from
consuming tobacco (65, 66), alcohol (67, 68), and stimulants (69)
(caffeine, theine, etc.) in the 24 h preceding the experimental
visit, and that they skip their last dose of pain medication
(acetaminophen, non-steroidal anti-inflammatory drugs, and
narcotics), such that they are not under the influence of an
analgesic agent during the session. Recreational substances are
also prohibited up to 7 days before the testing. Participants
who fail to adhere to these instructions will be asked
to reschedule their session. Participants will be recruited
using volunteer registers; Facebook advertisement, posters,
and leaflets; those interested will be invited to contact the




A number of psychological conditions are comorbidities of
chronic pain (7). For this reason, different psychological variables
will be evaluated.
Anxiety and Depression
The Hospital Anxiety and Depression Scale is an instrument used
to screen for anxiety and depressive disorders. It comprises 14
items (seven each for anxiety and depression) rated from 0 to 3,
for a maximum score of 21. Subjects are classified as presenting
no symptoms (≤7), mild symptoms (8–10), ormoderate to severe
symptoms (≥11) for both disorders. The psychometric properties
of this questionnaire are qualified as excellent (70).
Catastrophizing
The Pain Catastrophizing Scale (71) is a 13-item questionnaire
representing the three components of pain catastrophizing:
rumination, magnification, and helplessness. A score above 30/52
indicates a clinically significant level of catastrophizing. This
questionnaire has good psychometric properties (72).
Pain Measurements
Pain Intensity
The Brief Pain Inventory (BPI) (73) will be used to measure pain
intensity and interference with daily life. The BPI is a generic,
self-administered pain questionnaire for chronic pain conditions.
The psychometric qualities of this test are excellent (74–76).
Pain Type
The Douleur Neuropathique 4 (77) is a diagnostic tool used to
identify neuropathic pain. It assesses pain symptoms (type of pain
and presence of dysesthesia, out of seven) and signs (physical
examination, out of three). A score≥ 4/10 suggests a neuropathic
component. This tool is regularly used in research, and has
excellent psychometric properties (77).
General Clinical Pain
A pain diary will be used to measure daily clinical pain.
Participants with chronic pain will be asked to indicate the
highest, average and lowest level of pain they feel on seven
occasions (3 days prior to the visit, the day of the visit and the
3 days following the visit).
Somatization
The Somatization subscale of the Symptoms Checklist 90 (78, 79)
will be used to assess somatization in our participants. The
subscale comprises 12 items, each rated on a 5-point scale.
Psychometric properties of this subscale are excellent (79).
Mechanical Pain Threshold
A digital algometer will be used to assess the mechanical pain
threshold (i.e., the point at which a mechanical pressure starts to
elicit pain). The algometer will be placed on the upper trapezius
muscle, and the pressure will be gradually increased until the
participant verbally reports pain. Four trials will be conducted—
two on each side—and the average pressure required to reach the
mechanical pain threshold will be recorded. This test has good to
excellent reliability and validity (80–82).
Pain Persistence
A digital algometer will be used to assess pain persistence.
Following the mechanical pain trials described above, the
algometer will be applied on the right upper trapezius muscle,
and pressure will be increased until participants verbally report a
pain intensity of 5/10 (numerical rating scale). This pressure will
be maintained for 20 s (TonicMechanical Pain test). Immediately
after the algometer is removed, participants will be asked to
rate the intensity of their lingering pain sensation (if any), again
using the numerical rating scale. Pain scores will subsequently be




The cardiovascular system and the descending inhibitory
pathways of pain appear to be closely related (48, 75).
Blood pressure will be measured three times (at rest, before,
and after the conditioning stimulus—see below) using a
digital sphygmomanometer.
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Blood Concentration
Catecholamines (53) (adrenaline, noradrenaline, dopamine,
serotonin, and their metabolites), Endocannabinoids
(anandamide, N-olcoylethanilamine, palmitoylethanolamine),
and Peptides (83, 84) (Leu-Enképhaline, B-Endorphin,
Dynorphine A, Substance P). Blood samples will be collected
in K2-EDTA tubes and will be placed directly on ice. After
centrifugation (4◦C, 1,500 g, 15min), samples will be directly
stored at −80◦C before analysis. The different analytes will be
separated and analyzed by liquid chromatography coupled to a
tandemmass spectrometer. The analysis will be carried out at the
bioanalysis platform of the Sherbrooke Pharmacology Institute.
Dependent Variables
CPM and TS Amplitude
The amplitude of CPM and TS will be assessed within
a single experimental procedure, developed by Tousignant-
Laflamme (85) and in accordance with Yarnitsky (18, 86). This
procedure consists of a Test Stimulus applied before and after
a Conditioning Stimulus (CS); the amplitude of TS is measured
as the changes in pain levels observed throughout the first
administration of the Test Stimulus, and the amplitude of CPM
is measured as the difference in pain levels elicited by the Test
Stimulus before and after the CS. This method is commonly used
to measure these mechanisms (35, 55, 87, 88).
Pain Perception
Pain perception will be assessed using a Computerized Visual
Analog Scale (CoVAS). This tool, highly validated and commonly
used in research (89–91), consists of a slider placed along a
visual analog scale (left end: 0, or no pain; right end: 100, or
worst pain imaginable), linked to a computer. Participants move
the slider along the scale according to their pain levels, such
that their perceived pain intensity is continuously recorded by
the computer.
Procedure
At the beginning of the session, we will reassess participants’
eligibility, and we will collect their informed consent. We will
also collect data relating to our independent variables, using
a series of questionnaires, physiological measures, and a blood
sample. All questionnaires will be provided in each participant’s
preferred language (English or French). We will then assess the
amplitude of their CPM and TS using quantitative sensory testing
(Figure 1):
Thermode Calibration
Pre-tests will be conducted using an experimental thermode
(9 cm2, TSA II), at a temperature increasing from 32◦ to 51◦C at
a rate of 0.3◦C/s. Participants will be asked to identify the point at
which heat becomes painful (heat pain threshold) and the point
at which it becomes intolerably painful (heat pain tolerance).
One pre-tests will be conducted on the left hand of each
participant, so they become familiar with the thermode and
CoVAS. Three more pre-tests will be conducted on the anterior
side of the left forearm, to identify the average temperature
eliciting a pain intensity of 50/100. This temperature will be used
as the Heat Test Stimulus (see below).
Pre-CS Test Stimuli
Two Pre-CS Test Stimuli will be used in our study: a painful
mechanical pressure and a painful heat stimulus. TheMechanical
Test Stimulus will be administrated using the digital algometer,
applied on the upper trapezius muscle at the mechanical pain
threshold (see Independent Variables—Mechanical pain). The
average pressure required to reach the mechanical pain threshold
before and after the CS will be compared to assess CPM.
The second Test Stimulus will consist of a 2min heat pain
stimulation, delivered by the thermode applied on the left
forearm of participants, at an individually tailored temperature
selected to evoke pain levels of 50/100 (based on the pre-tests).
Although the thermode temperature will be kept constant during
the stimulation (following a gradual increase from 32◦C to the
target temperature, at a rate of 0.3◦C/s), participants will be told
that the temperature will randomly vary (increase, remain stable,
or decrease). Participants will be asked to rate their pain during
the stimulation using the CoVAS. This Heat Test Stimulus will
serve two purposes: first, like the Mechanical Test Stimulus, it
will be used as a pre- and post-CS comparator to assess CPM;
second, it will be used to evaluate TS, which will be measured as
the change in pain levels throughout the heat test stimulation.
Conditioning Stimulus (CS)
The conditioning stimulus, which serves to trigger CPM, will
consist of the Cold Pressor Test, wherein participants immerse
their right arm (up above the elbow) in a painfully cold water
bath [10◦C; (44)] for 2min. This technique has been shown to
consistently elicit CPM (92).
Post-CS Test Stimuli
The Heat Test Stimulus will be administered again immediately
after the CS, using the same parameters as for the pre-CS
stimulation. Following this, the Mechanical Test Stimulus will
also be re-administered; again, four trials will be conducted and
the average pressure corresponding to the pain threshold will be
recorded. Comparisons between pre-CS and post-CS scores will
be used to assess CPM.
ETHICAL ASPECTS
This study will be conducted in accordance with the Helsinki
Declaration and the International Council for Harmonization
of Good Clinical Practices. Participants will be informed of the
purpose and process of this study. We will collect their written
informed consent, reminding them that participation in this
study is purely voluntary and that they can withdraw at any
time without negative repercussions, and we will preserve the
confidentiality of their data. Participants will be asked to skip only
the dose of their analgesic medication immediately preceding
the experimental session, to minimize undue pain. The trial is
registered at clinicaltrial.gov (NCT03376867).
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FIGURE 1 | Illustration representing the sequence of the experimental procedure.
STATISTICAL CONSIDERATIONS
Sample Size
It is customary in predictive analysis to use a rule of thumb
to calculate the sample size, wherein the number of subjects
required for a multiple regression analysis is n = 10–15
subjects per variable (93). However, this rule often yields fitted
models with limited predictive capabilities (94–98); as such, it is
recommended that two cohorts be used: a discovery cohort, and
a validation cohort—which, as their names suggest, are used to
build the predictive model and to validate it, respectively (99).
We calculated a sample size of 360 participants for the
discovery cohort, based on the smallest expected R2 (0.4) and
the highest expected number of predictors (24) required to
obtain a shrinkage coefficient (100) of at least 0.9 (101). The
discovery cohort will be representative of the overall population,
such that it will be comprised of 85% (n = 306) of healthy
participants and 15% (n = 54) of patients suffering from chronic
pain (102). The external validation cohort will be comprised of
54 (new) participants, corresponding to 15% of the size of the
discovery cohort (103). We will use two such validation cohorts
(n = 54 for both) in order to validate our model using both
healthy participants and patients suffering from chronic pain. As
such, a total of 468 participants will be recruited (360 healthy
participants, and 108 patients suffering from chronic pain).
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TS and CPM Amplitude
The amplitude of TS (ATS) will be measured as the difference
in pain intensity elicited by the thermode during the heat test
stimulation (first instance the Heat Test Stimulus). We will
subtract the pain level at 0 s (time the thermode reaches the
target temperature) from the pain level at 120 s, so that a positive
score represents an increase in pain level. The amplitude of CPM
(ACPM) will be measured as the difference in pain level elicited by
the thermode (calculated as the average of all pain scores taken
throughout the 2min test stimulation) before and after the cold
water bath, and as the difference in pressure required to reach
mechanical pain threshold before and after the cold water bath.
Statistical Analyses
The sample will be characterized using descriptive statistics. The
underlying assumptions of the regression model will be verified
by analyzing the residuals distribution.
The main objective (identifying predictors of excitatory (TS)
and inhibitory (CPM) endogenous pain mechanisms) will be
achieved through the development of two predictive models
(one for each mechanism). Development of a predictive model
requires two steps: (1) Building and (2) Validation, which each
use their own participant cohorts (see Sample Size section).
Building involves a data-driven selection of the variables to
be included as predictors in the model; for each variable, the
beta coefficient is calculated and fitted to the model. Validation
involves testing the model with data from new participants, in
order to quantify the predictive capacity of the model. Validation
will be conducted twice for each model: once with a healthy
cohort, and once with a chronic pain cohort.
We will use a lasso regression on the discovery cohort to
determine which variables will be included in the model for
each mechanism. Lasso regression fits a linear model between
an outcome and a set of predictors by adding a penalty term
that shrinks coefficients associated to poor predictive capacity
variables to 0 (i.e., Lasso automatically excludes poor predictors).
This approach thus encourages simple and sparse models,
and is widely used to perform variable selection in prediction
contexts (103). The penalty term involves a coefficient (often
denoted by lambda) that determines the amount of shrinkage
to perform. This coefficient is often set so as to maximize a
cross-validation estimate of the predictive capability of a model
(103). Accordingly, we will select the shrinkage coefficient that
minimizes the leave-one-out cross-validation estimate of the
mean square prediction error. The resulting “optimal” shrinkage
coefficient will be used within the lasso regression model, and
the predictors and non-zero fitted parameters will be retained to
constitute our predictive model.
In order to complete the validation (validation cohort), we
will calculate the mean square prediction error of the predictive
model for the healthy and chronic pain cohorts. If the mean
square prediction error is smaller than 10%, the model will be
considered to have a good predictive value. We will compare this
predictive error between the two populations, to assess whether
predictors are the same between healthy and patient populations.
The second objective (i.e., estimating reference TS and CPM
values in healthy subjects) will use data from the 360 healthy
participants (306 from the discovery cohort and the 54 from
the healthy validation cohort). Participants will be separated into
subgroups based on biological sex (male, female) and age (18–39,
40–59, and 60–79 years old), for a total of six subgroups. For
each subgroup, a kernel estimation method will be used to obtain
density curves, from which percentile reference charts will be
generated (104). These analyses will be run separately for TS and
CPM data.
DISCUSSION
To our knowledge, this is the first protocol that single handedly
studies psychological, physiological and socio-demographic
markers of endogenous pain modulation mechanisms.
The protocol we adopted to assess TS and CPM is frequently
used in our laboratory; its reliability has been validated (10–12),
and our expertise with the procedure and our familiarity
with the equipment considerably reduces the risk of bias and
confounding factors.
Chronic pain is a highly prevalent condition, for which there
is currently no satisfying treatment approach. The success rates
of surgery are subpar (105, 106); therapeutic exercises (107) only
have limited success; and the current pharmacological approach,
which relies mostly on drawn-out trial and error, is disheartening
for both the patients, who struggle to see a finality to their pain,
and the clinicians, who are confronted with their powerlessness
in the face of their patients’ everlasting ailment (108).
It is becoming more and more apparent that chronic pain
treatment should focus not on the symptomatology—or type
of condition—of chronic pain patients, but rather on the
underlying imbalance in their pain modulation mechanisms. The
amplitude of CPM and TS has been shown to correlate with
the development of chronic pain conditions (109, 110), which
imparts them with a predictive quality that could be extremely
useful in clinical practice. Moreover, specific assessments of CPM
and TS can effectively predict treatment success rates in patients
suffering from chronic pain (27). As such, an individualized
pharmacological treatment informed by the pain modulation
profile of each patient could significantly improve treatment
outcome. Unfortunately, current CPM and TS testing procedures
remain too expensive and time-consuming to be used on a
regular basis in hospitals or family medicine clinics.
This study will further our understanding of modulatory
mechanisms and their relationship with a complex system of
physiological, psychological and socio-demographic correlates,
which will allow us to develop a predictive model to compute
the pain modulation profile of individual patients based on
their biopsychosocial characteristics. This model will consist in a
simple equation in which clinicians can input the value of selected
variables (obtained via simple clinical tests), in order to yield the
predictive amplitude of their patients’ CPM and/or TS response.
The overarching goal of this study is to provide clinicians with
a set of quick and cheap tests, easily applicable in day-to-
day practice, in order to identify markers of pain modulation
profiles and in turn orient pharmacological treatment, which
will ultimately provide patients with a more hopeful outlook on
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their future and will lead to a more optimal use of ever limited
health care resources. This protocol is the first step toward the
development of a validated clinical tool.
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